Compare

IN8BIO, Inc. vs Inmune Bio, Inc. vs Jasper Therapeutics, Inc. vs Champions Oncology, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearIN8BIO, Inc.
INAB
Inmune Bio, Inc.
INMB
Jasper Therapeutics, Inc.
JSPR
Champions Oncology, Inc.
CSBR
Year ended2025-12-312025-12-312025-12-312026-04-30
Revenuen/a$50.0Kn/a$59.42M
Revenue growth (YoY)n/a+257.1%n/a+4.4%
Gross marginn/an/an/a48.0% (computed)
Operating marginn/an/mn/a-1.9%
Net marginn/an/mn/a-2.0%
Net income-$19.44M-$45.93M-$75.80M-$1.18M
EPS (Diluted)-$4.44-$1.86-$3.95-$0.08
Operating cash flow-$12.71M-$22.58M-$77.16M-$4.47M
Free cash flown/a-$23.62Mn/a-$5.04M
Cash & equivalentsn/a$24.75M$28.69Mn/a
Total assets$32.28M$32.35M$35.78M$26.99M
Total liabilities$4.72M$8.83M$31.63M$22.92M
Shareholders' equity$27.56M$23.52M$4.15M$3.94M
Return on year-end equity-70.5%-195.3%n/m-29.8%
Shares outstanding9.77M26.59M28.00M13.89M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearIN8BIO, Inc.Inmune Bio, Inc.Jasper Therapeutics, Inc.Champions Oncology, Inc.
Latestn/a$50.0K
Ended 2025-12-31
n/a$59.42M
Ended 2026-04-30
1 year earliern/a$14.0K
Ended 2024-12-31
n/a$56.94M
Ended 2025-04-30
2 years earliern/a$155.0K
Ended 2023-12-31
n/a$50.16M
Ended 2024-04-30
3 years earliern/a$374.0K
Ended 2022-12-31
n/a$53.87M
Ended 2023-04-30
4 years earliern/a$181.0K
Ended 2021-12-31
n/a$49.11M
Ended 2022-04-30